Abstract：ObjectiveTo compare cost effectiveness by Morphine sulfate sustained-release tablets,Oxycodone hydrochloride prolonged-release tablets,Fentanyl transdermal patches and Buprenorphine transdermal patches in the treatment of primary hepatic carcinoma pain.MethodsFrom April 2015 to April 2017,100 patients with pain of primary liver cancer were selected and randomly divided into four groups(A,B,C and D)according to different administration methods,with 25 cases in each group.Group a was given Morphine sulfate sustained release tablets,group B was given oxycodone hydrochloride sustained release tablets,group C was given Fentanyl transdermal patch,group D was given buprenorphine transdermal patch.After treatment for 30 days,the efficacy,adverse reactions and quality of life of the four groups were observed,and cost-effectiveness analysis was carried out.ResultsGroup B and C had higher analgesic effect than group A and D.There was no significant difference in the analgesic effect between the four groups(P＞0.05).there was no significant difference in the incidence of adverse reactions between the four groups after 1 month of drug use (P＞0.05).A-mong them,the adverse reactions in group B(Oxycodone hydrochloride sustained release tablets group)were less.There was significant difference between the four groups before and after treatment(P＜0.001),but there was no significant difference between the four groups(P=0.059).After two-to-two comparison of the four groups,it was found that there was significant difference between group A and group B(P=0.026),group B and group D(P=0.031),the quality of life among the other groups improved,there was no significant difference(P＞0.05);BC/E＜AC/E＜CC/E＜DC/E,there was no significant difference in the efficiency of cost-effect analysis among the four groups(P＞0.05).ConclusionThere were no significant differences in the effective rate of treatment by using four drugs.Compared the adversereactions and quality of life,the oxycodone hydrochloride prolonged-release tablets was the best schedule in the treatment of primary hepatic carcinoma pain from pharmaconomics.
京公网安备 11010502046607号